SSG
AGIO icon

Summit Securities Group’s Agios Pharmaceuticals AGIO Stock Holding History

Summit Securities Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.8K Buy
+408
New +$11.6K ﹤0.01% 601
2013
Q4 		– Sell
-100
Closed -$3K – 508
2013
Q3 		$3K Buy
+100
New +$2.76K ﹤0.01% 318

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Summit Securities Group's AGIO Position: Q1 2026 in Review

Summit Securities Group opened a new position in Agios Pharmaceuticals (AGIO) in Q1 2026: 408 shares worth $13.8K. The stake represents ﹤0.01% of the portfolio and ranks #601 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in AGIO as recently as Q3 2013.

Summit Securities Group first reported a position in AGIO in Q3 2013 and has held it in 2 quarters since. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Summit Securities Group held 408 shares of Agios Pharmaceuticals worth $13.8K as of Q1 2026.
  • Agios Pharmaceuticals was a new Summit Securities Group position in Q1 2026.
  • Agios Pharmaceuticals made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #601 holding.
  • Summit Securities Group first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 2 quarters since.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.